- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01554020
Blood Sugar Take Care and Glucose Metabolism
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
California
-
San Francisco, California, Verenigde Staten, 94109
- SPRIM
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
SUBJECT INCLUSION CRITERIA: STEP 1
- Age ≥ 18 years
Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- Have a first-degree relative with diabetes
- Habitually physically inactive
- Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- Hypertensive (≥140/90)
- Known HDL cholesterol level 35 mg/dl
- Known triglyceride level ≥250 mg/dl
- On previous testing, had impaired glucose tolerance or impaired fasting glucose
- History of vascular disease
- Stable body weight (<5% change) in the last 3 months
- Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- Able to understand the nature and purpose of the study including potential risks and side effects
- Willing to consent to study participation and to comply with study requirements
SUBJECT EXCLUSION CRITERIA
- Known diabetes (type I or II)
- Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- Eating disorder
- Polycystic ovary syndrome
- Known allergies to any substance in the study product
- Pregnant or breastfeeding women
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
SUBJECT INCLUSION CRITERIA: STEP 2
1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
SUBJECT INCLUSION CRITERIA: STEP 3
- Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Multiherb product
Herbal product
|
One 1200 mg soft gel capsule administered 3X/day for duration of study
Andere namen:
|
|
Placebo-vergelijker: Placebo
Maltodextrin control
|
One 1200 mg soft-gel capsule administered 3X/day for duration of study
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Nuchtere glucose
Tijdsspanne: 12 weken
|
12 weken
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Bijwerkingen
Tijdsspanne: 12 weken
|
12 weken
|
|
|
Bloeddruk
Tijdsspanne: 12 weken
|
12 weken
|
|
|
Insulinegevoeligheidsindex
Tijdsspanne: 12 weken
|
12 weken
|
|
|
Nuchtere insuline
Tijdsspanne: 12 weken
|
12 weken
|
|
|
Homeostasis Model Assessment of Insulin Resistance
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Quantitative insulin sensitivity check index
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Insulin secretion/insulin resistance index
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Geglycosyleerd hemoglobine (HbA1c)
Tijdsspanne: 12 weken
|
12 weken
|
|
|
High-sensitivity C-reactive protein
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
High-molecular weight adiponectin
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Body composition
Tijdsspanne: 12 weeks
|
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
|
12 weeks
|
|
WHO Quality of Life Questionnaire
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Comprehensive metabolic panel
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Volledig bloedbeeld
Tijdsspanne: 12 weken
|
12 weken
|
|
|
Gastrointestinal Symptom Rating Scale
Tijdsspanne: 12 weeks
|
12 weeks
|
|
|
Pulse
Tijdsspanne: 12 weeks
|
12 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Larry Miller, PhD, Sprim Advanced Life Sciences
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 120216-SUS-NWC-BSS-GP
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .